HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a $150 price target.
April 24, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Neurocrine Biosciences with a $150 price target.
The reiteration of a Buy rating and a high price target by a reputable analyst suggests a strong bullish sentiment towards NBIX. This endorsement could positively influence investor perception and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100